Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04032080
Title Treatment With Oral LY3023414 To Inhibit Homologous Recombination Followed By Prexasertib (ExIST)
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Baylor Research Institute
Indications

triple-receptor negative breast cancer

Therapies

Prexasertib

LY3023414

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.